Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Our latest clients all have the potential to grow significantly in the near and long-term future

Re: Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Postby QualityStocks » Tue Aug 29, 2017 4:45 pm

NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Scheduled to Attend Two Cannabis Conferences in September

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), a company engaged in licensing proprietary technology for the delivery of bioactive compounds, this morning announced its plans to attend two cannabis investment conferences in September. The first, the Investorshub International Cannabis Conference, will be held at the JW Marriott in downtown Los Angeles on September 1-2. The second, the Institutional Capital & Cannabis Conference (East), is scheduled to take place on September 7-8 in Miami Beach. This morning’s news release also included an update on the company’s financing activities. Notably, Lexaria has received and executed a notice of conversion related to certain convertible debt, extinguishing a $45,000 convertible debt plus interest in exchange for 307,500 restricted common shares at the contracted conversion price of $0.15. The company also issued 32,433 common shares, at a conversion price of $0.37, to a director in order to settle $12,000 of debt.
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 613
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Postby QualityStocks » Thu Aug 31, 2017 4:03 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Begins Laboratory Venture with National Research Council

- Collaborative venture could lead to strengthening of company’s patent portfolio, new commercial opportunities
- Firm receives patent in Australia, anticipates entering that market through cannabinoid licensing arrangements and product distribution partnerships
- LXRP names Allan Spissinger acting chief financial officer

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has begun laboratory work with the National Research Council (“NRC”) (http://nnw.fm/ujFU0). The collaboration will begin studies using LXRP’s patented technologies. The research will include the company’s technology in vitamins, NSAIDs, nicotine and cannabinoids utilizing lipophilic active agents. LXRP has patented technology involving how those agents are ingested into the human body in various edibles, such as beverages, foods, capsules and others means.

LXRP has also named Allan Spissinger (http://nnw.fm/kcVB3) as its acting chief financial officer, secretary and treasurer. He has been with the company since September 2014, when he joined as corporate controller. A CPA, he has more than 10 years’ experience in corporate IT infrastructure and software development before focusing of finance and accounting.

The firm, based in Kelowna, British Columbia, Canada, is a food biosciences company which is a technology disrupter for edible CBDs. It markets a high absorption hemp oil formulation for exotic teas, protein energy bars and high absorption hemp oil capsules that aid in the body’s absorption of CBDs. It is focusing on developing more products for the edible cannabis market.

The joint research venture with the NRC will use advanced analytical techniques. Practical application of the resulting research could broaden or strengthen LXRP’s intellectual property portfolio and even lead to additional commercial arrangements, per a recent statement from the company.

LXRP has a number of international patents, including the recent 20-year effective patent approval issued by Australia (http://nnw.fm/R0nZZ) for the company’s edible cannabis absorption method, time of onset and taste of cannabinoid’s active agents in food.

“We are very pleased to have received this patent which effectively covers all cannabis oil extract formulated edibles using our technology in Australia,” Chris Bunka, chief executive officer of LXRP, stated in a news release. “This patent award allows us to confidently enter the recently legalized Australian cannabis marketplace where we will seek additional licensing and product distribution partnering opportunities.”

A similar patent was granted in the U.S. in 2016, and Bunka added that LXRP anticipates progress on its patent portfolios throughout the remainder of 2017 and into 2018. In the U.S., the company successfully filed a provisional patent application (http://nnw.fm/Gle8p) and stock and option awards in June 2017. It expands the company’s existing patent in the U.S. to microwave processing.

For more information, visit the company’s website at www.LexariaEnergy.com
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 613
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Postby QualityStocks » Thu Aug 31, 2017 4:13 pm

NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Announces Clinical Study of High Absorption TurboCBD™ Product

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), a company engaged in licensing proprietary technology for the delivery of bioactive compounds, this morning announced the world’s first clinical study on human volunteers of cannabidiol (CBD) within Lexaria’s TurboCBD™ product. The study, which aims to evaluate the effects of TurboCBD™ on both cardiovascular health and cognitive function, will have a double-blind and placebo controlled cross-over design measuring effects after a single dose, as well as seven days of daily dosing, in 24 volunteers. “Lexaria is proud to be advancing our collective knowledge of the benefits of CBD specifically showcasing the benefits of Lexaria’s unique patented delivery technology,” Chris Bunka, CEO of Lexaria, stated in the news release. “Results will advance Lexaria’s ability to custom design products that increase the leading performance our technology already offers to customers.”
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 613
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Postby QualityStocks » Wed Sep 06, 2017 4:04 pm

Landmark M&A Deals Continue to Shape Big Pharma

NetworkNewsWire Editorial Coverage: Merger and acquisition activity has played a massive role in the formation of the pharmaceutical industry as it exists today. Historic deals, like Pfizer’s 2009 purchase of pharmaceutical giant Wyeth for $68 billion and Glaxo Wellcome’s purchase of SmithKline Beecham for $76 billion in 2000, have created a consolidated market that’s often driven forward by the innovations of smaller companies. Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) (LXRP Profile), with its promising intellectual property portfolio focused on revolutionizing the delivery of a variety of molecules to the human body, is well-positioned to continue on this history of acquisition in the pharmaceutical space, following in the footsteps of companies like Derma Sciences, Inc., which was acquired by Integra LifeSciences Holdings Corporation (NASDAQ: IART) for approximately $200 million, and CoLucid Pharmaceuticals, Inc., which was acquired by Eli Lilly and Company (NYSE: LLY) in a landmark $960 million deal. With analyst rumblings pointing toward additional high-profile buyouts of industry upstarts like ACADIA Pharmaceuticals, Inc. (NASDAQ: ACAD) and Incyte Corp. (NASDAQ: INCY), the time to cash in on the next Big Pharma acquisition could be at hand.

While the acquisition frenzy in pharmaceuticals spans the entirety of the colossal global industry, few subsectors have demonstrated more potential for promising upstarts than the medicinal cannabis market. Projected by Arcview Market Research to eclipse $20.2 billion in North American sales by 2021, the legal marijuana industry, including both medicinal and recreational markets, is expected to create more than a quarter of a million jobs by 2020, outpacing economic mainstays like manufacturing, utilities and government positions. This forecast expansion has already set the stage for a number of industry acquisitions, many of which have taken place in the soon-to-be federally legalized Canadian market. One such is example Canopy Growth Corp.’s April acquisition of rTrees Producers Limited, a late-stage Access to Cannabis for Medical Purposes Regulations (“ACPMR”) applicant. The rTrees acquisition brought a 90,000 square foot indoor growing facility with considerable room for expansion under Canopy Growth’s already sizable umbrella, expanding upon the market presence of the first Canadian cannabis company to achieve a $1 billion market valuation.

Other industry players have followed Canopy Growth’s lead. In late July, Aurora Cannabis announced plans to make a strategic investment in Hempco Food and Fiber, Inc., one of the world’s largest producers of industrial hemp products. Earlier that same month, Canadian cannabis producer Invictus MD Strategies Corp. invested $5.5 million in AB Ventures, Inc. to fund the costs of licensing approval under the ACMPR and construction of related production facilities. Similar M&A deals were recently completed by Aphria, which invested $11.5 million in endocannabinoid-focused pharmaceutical company Scientus Pharma in mid-August, and Maricann Group, Inc., which recently announced its acquisition of biotech company NanoLeaf Technologies for total transaction consideration of C$40.1 million. The NanoLeaf transaction is particularly intriguing for prospective investors of Lexaria Bioscience, as NanoLeaf possesses “the licensing rights to a number of globally patented technologies that provide proven pharmaceutical, nutraceutical, cosmetic and functional beverage drug delivery formulations.”

This recent industry activity highlights the rising demand for innovative and marketable offerings targeting the burgeoning cannabis sector, but they fail to capture the scale of a potential Lexaria Bioscience transaction. This is because of the wide-ranging applications of Lexaria’s technology platform. To date, the company has noted potential applications for its lipid-based molecular delivery technology that include NSAIDs, nicotine, vitamins and cannabinoids – applications that are supported by 19 currently-pending patents filed in more than 40 countries. According to biotech analysis firm EvaluatePharma, the global market for NSAIDs was valued at $11.4 billion in 2014. Meanwhile, the global market for vitamins in on course to reach $9.3 billion by 2020, the market for alternative nicotine delivery technologies is at an all-time high following recent FDA proposals, and consumer sales of cannabinoids are expected to reach $2.1 billion by 2020. All told, the market potential for Lexaria’s flagship platform could be huge.

It has been precisely this potential, alongside numerous clinical, financial and IP developments, that has driven Lexaria’s growth in recent months. On July 18, the company announced (http://nnw.fm/wI0LB) that the Australian Patent Office granted a patent protecting its method of improving absorption, speed of onset and taste of cannabinoid active agents in edible products. This milestone was particularly noteworthy in that it followed Lexaria’s announcement of a $1 million combined R&D program aimed at examining improvement in absorption offered by its technology for several groups of molecules, including NSAIDs, nicotine, vitamins and cannabinoids. Just last week, the company took a major step toward maximizing on the value of its patented technology by announcing the world’s first clinical study of human volunteers of CBD within its high absorption TurboCBD™ product.

“Lexaria is proud to be advancing our collective knowledge of the benefits of CBD specifically showcasing the benefits of Lexaria’s unique patented delivery technology,” Chris Bunka, CEO of Lexaria, stated in the news release announcing the study. “Results will advance Lexaria’s ability to custom design products that increase the leading performance our technology already offers to customers.”

Strengthening Lexaria’s status as a promising acquisition target is its current cash position. The company has outlined a number of moves to bolster its balance sheet in recent months, most notably its $1 million raise from warrant exercise originally announced on May 19. In total, Lexaria raised over $3 million in the past nine months in a strategic effort to capitalize on the growth of both the pharmaceutical industry as a whole and, perhaps more importantly, the cannabis sector. With funding in place through 2019, according to Bunka, Lexaria has the IP and the capital needed to properly demonstrate the marketability of its lipid-based delivery technology while working with prospective licensees and resellers to maximize returns for early investors.

Recent acquisitions in the pharmaceuticals industry highlight the potential upside Lexaria presents to the investment community. Derma Sciences, Inc., for example, operated as a tissue regeneration company at the forefront of research and innovation for the management of acute and chronic wounds prior to its acquisition by Integra LifeSciences Holdings Corp. (NASDAQ: IART) in January of this year. In a slide deck issued following the acquisition, IART noted Derma’s “line of products with patented technologies,” including multiple offerings targeting the burn and wound management market, as a key driver for the transaction. Insights from medical technology analysis firm MedMarket Diligence, LLC suggest that this market is currently growing at a rate of 3.1 percent annually, providing a fertile runway for future sales growth in the space. For comparison, the cannabinoid market, which is just one of many potential indications for Lexaria’s molecular delivery technology, is expected to climb 700 percent from 2016-2020.

Eli Lilly and Company’s (NYSE: LLY) March acquisition of CoLucid Pharmaceuticals, Inc. serves as another example of the aggressive M&A strategy employed by some of the most recognizable names in Big Pharma. At the time of the deal, David R. Ricks, president and chief executive officer of Eli Lilly, noted that the purchase would “enhance Lilly’s existing pain management portfolio and add a potential near-term launch to [its] late-stage pipeline.” This late-stage addition is lasmiditan, an oral tablet that’s currently being evaluated in phase III clinical trials for the acute treatment of migraine headaches in adults. Lasmiditan was actually originally developed by Eli Lilly, but it was licensed to CoLucid in 2005 as part of Lilly’s strategic move away from the pain management market. On top of highlighting the evolving strategies of Big Pharma players to capitalize on industry trends – including cannabis painkillers and related cannabinoid products – the CoLucid acquisition’s focus within the migraine drug market falls well within earshot of Lexaria’s diverse portfolio of potential applications for its lipid-based delivery technology.

In both of these cases, high-dollar acquisitions were fueled by strong intellectual property positions targeting inviting markets within the pharmaceutical industry. This trend rings true when studying other upstart companies that could be in line for big time buyouts. A buyout of ACADIA Pharmaceuticals, Inc. (NASDAQ: ACAD) has been rumored for months, with the company having reportedly received an offer from AstraZeneca in February and interest from Pfizer related to its lead product NUPLAZID®, the only significant compound in the company’s development pipeline. Approved by the FDA for the treatment of hallucinations and delusions associated with Parkinson’s disease, NUPLAZID® is currently in late stage trials for similar symptoms in Alzheimer’s and schizophrenia, giving it the potential to address a massive and growing global market. The company’s stock closed at $36.16 on September 1, and reports from Seeking Alpha suggest that ACADIA’s management team is pushing for a substantial premium for a potential buyout in the range of “$55 to $60 a share.”

Incyte Corp. (NASDAQ: INCY) is another prime buyout target, as reported in an editorial piece published by MarketWatch. “Incyte is a throwback to what biotech companies were meant to be,” RBC Capital Markets analyst Simos Simeonidis told MarketWatch. “It’s built on ‘great science’ that has helped it develop several drugs, and it continually reinvests in its own research.” Incyte’s main product, Jakafi, is an FDA-approved medication used to treat rare blood cancers. Back in March, analysts speculated that Gilead was close to an agreement to acquire Incyte. Although that deal has not yet come to fruition, the Delaware-based company offers a combination of growing revenues and strong R&D programs that makes it a solid acquisition target, particularly as disappointing clinical data from competing trials strengthen the revenue outlook of Incyte’s leading product.

As demonstrated by recent industry activity, Big Pharma’s biggest names stay active on the M&A front, especially as it relates to first-of-their-kind advancements in promising markets. Continued interest in the pipelines of upstarts like ACADIA Pharmaceuticals and Incyte Corporation paints an intriguing picture as Lexaria Bioscience progresses with the world’s first clinical study of CBD within its high absorption TurboCBD™ product. With a strong balance sheet and an increasingly diverse and wide-reaching IP portfolio targeting some of the industry’s highest growth verticals, Lexaria should be on the radar of any investor hoping to cash in on the M&A deal-making bonanza that could be on the horizon.

For more information on Lexaria Bioscience Corp., please visit: Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 613
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Postby QualityStocks » Thu Sep 07, 2017 4:07 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Continues Showcasing Proprietary Research at Cannabis Investment Conferences

- Proprietary Lexaria technology improves delivery of bioactive compounds in a variety of products, including cannabis-based gourmet foods
- Market predictions for the legal marijuana industry forecast $50 billion in sales by 2026
- 19 patent applications filed and pending in more than 40 countries

Following a successful showing at the inaugural Institutional Capital & Cannabis Conference (IC3) in California earlier this month, Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) CEO Chris Bunka expects the company to be noticed by investors. Bunka’s presentation of the company’s latest technology slated to benefit the cannabis industry includes the world’s first clinical study on human volunteers of cannabidiol (CBD) within Lexaria’s TurboCBD™ product.

The study, which aims to evaluate the effects of TurboCBD™ on both cardiovascular health and cognitive function, will have a double-blind and placebo controlled cross-over design measuring effects after a single dose, as well as seven days of daily dosing, in 24 volunteers (http://nnw.fm/Uh5R4).

“Results will advance Lexaria’s ability to custom design products that increase the leading performance our technology already offers to customers,” Bunka said in a press release outlining the project.

While Hurricane Irma has postponed Bunka’s next mainstream presentation, slated for the now on-hold Institutional Capital & Cannabis Conference in Miami Beach, Florida, Lexaria continues its drive to showcase the benefits of the company’s unique patented delivery technology (http://nnw.fm/e7OkE).

Lexaria researchers work to solve a critical problem facing the cannabis industry – the fact that most of the CBD and tetrahydrocannabinol (THC) that people consume, through any method, is literally flushed away in the proverbial toilet. To that end, Lexaria has focused on discovering new technologies that can more efficiently deliver cannabinoids to the bloodstream, where they can have their desired effect.

Lexaria’s patented DehydraTECH™ technology solves this problem by delivering cannabinoids in an oral form that masks any undesirable taste but increases bioabsorption, speed of effectiveness and potency. This method of delivery is a more viable and healthier method than smoking or vaping cannabis, a route that non-users and medical providers frown upon due to documented health concerns.

Marijuana is now legal in some form in 29 states and Canada. In fact, the Canadian government is expected to legalize adult use of cannabis in 2018, and there are growing movements in the U.S. to legalize cannabis nationwide, as well. Industry experts predict that U.S. retail sales alone could reach $50 billion by 2026 (http://nnw.fm/0mG2S).

For more information, visit the company’s website at www.LexariaEnergy.com
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 613
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Postby QualityStocks » Wed Sep 13, 2017 4:20 pm

Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQB: LXRP) Oral CBD Product to Be Tested by the University of British Columbia

- The University of British Columbia (UBC) will conduct a double-blind study of Lexaria’s TurboCBD™ oral ingestion product
- TurboCBD™ masks foul tastes, protects pharmaceutical ingredients during stomach passage and increases intestinal absorption by 5-10x
- The UBC study will include 24 volunteers and test their cognitive and cardiovascular function after single doses and after seven days of administration

Traditionally, cannabidiol (CBD) is ingested via inhalation, which can harm the lungs, and many edible products contain unwanted sugars or sweeteners. Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has revolutionized oral intake with its TurboCBD™ product. Engineered to increase absorption through the intestinal tract, without active compounds destroyed by stomach acid or broken down by the liver, the product also masks the flavor of compounds with undesirable tastes. In August 2017, the University of British Columbia (UBC) announced (http://nnw.fm/3GYyd) that it will conduct the first clinical study of the high-absorption product while evaluating its effects on cognitive function and cardiovascular health of human volunteers.

Currently, Lexaria is the only company to have been awarded a patent for delivery of ingestible non-psychoactive cannabinoids. It holds patents in the U.S. and Australia, and more are pending in over 40 other countries. The upcoming UBC study will be double-blind and placebo controlled. Researchers will measure the effects after a single dose and after seven days of daily doses. The 24 volunteers will consist of young and old individuals, whose glucose, blood pressure, vascular function, cognition, and physical performance will be measured. Blood samples, exercise tests, heart rate, respiration, and neuropsychological tests, among other measurements, will be conducted as well. These tests will provide a complete set of pharmacokinetic and pharmacodynamic performance data of Lexaria’s TurboCBD™.

Regarding the expected outcome of the study, professor Philip Ainslie, PhD, stated in the recent report, “…To quantify the pharmacokinetics of TurboCBD™ will allow us to make informed recommendations of optimum dosing in order to improve vascular health and performance throughout healthy aging. Once we understand these processes better, the applications to various clinical populations can then be explored…”

Details of the test results are expected to be released once the study is completed and the data are interpreted.

According to Lexaria, its “plant-to-bloodstream” product amplifies intestinal absorption by 5-10x. It uses fatty acids, which combine with the active pharmaceutical ingredient to block them from bitter taste receptors on the tongue. Active ingredients are protected by lipids as they pass through the stomach. In the small intestine, long chain fatty acids are absorbed directly into the lymphatic system, while medium chain fatty acids are absorbed via the liver.

An August 2015 in vitro absorption study, conducted in a third party lab, found a 499 percent increase in CBD bioabsorption in the intestines. A human focus study in March 2016 revealed the onset of THC effects in 15 to 20 minutes, while test subjects praised the taste of the product. The company also entered into a collaborative research agreement with Canada’s National Research Council, which was signed in February 2017.

For more information, visit the company’s website at www.LexariaEnergy.com
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 613
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Postby QualityStocks » Fri Sep 15, 2017 4:07 pm

NetworkNewsBreaks – University of British Columbia to Conduct Clinical Study of Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQB: LXRP) Game-Changing Oral CBD Product

While cannabidiol and other marijuana-derived substances are traditionally smoked, this can cause damage to the lungs, and edible cannabis products have their drawbacks, too—typically being filled with sugars or other sweeteners to mask the unpleasant flavor associated with cannabis compounds. With its pioneering TurboCBD™ product, however, Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has revolutionized oral CBD intake, having engineered the product to enhance absorption through the intestinal tract without active compounds being destroyed by stomach acid or broken down by the liver, and this revolutionary product also masks the unpleasant flavor of cannabis compounds. An article further discussing this topic reads: “In August 2017, the University of British Columbia (UBC) announced (http://nnw.fm/3GYyd) that it will conduct the first clinical study of the high-absorption product while evaluating its effects on cognitive function and cardiovascular health of human volunteers. Currently, Lexaria is the only company to have been awarded a patent for delivery of ingestible non-psychoactive cannabinoids. It holds patents in the U.S. and Australia, and more are pending in over 40 other countries. The upcoming UBC study will be double-blind and placebo controlled. Researchers will measure the effects after a single dose and after seven days of daily doses. The 24 volunteers will consist of young and old individuals, whose glucose, blood pressure, vascular function, cognition, and physical performance will be measured. Blood samples, exercise tests, heart rate, respiration, and neuropsychological tests, among other measurements, will be conducted as well. These tests will provide a complete set of pharmacokinetic and pharmacodynamic performance data of Lexaria’s TurboCBD™.”
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 613
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Postby QualityStocks » Tue Sep 19, 2017 4:00 pm

Advances in Drug Delivery Hold the Promise of Reducing Inevitable Side Effects

NetworkNewsWire Editorial Coverage: The hazards of pharmacology have hardly changed since Paracelsus, a famous Renaissance physician, astoundingly declared that it was only the dosage that separated a medicine from a poison, bundled with adverse side effects. Despite considerable advances in medicine, many medications are still as injurious as their Renaissance precursors. Nevertheless, recent developments in drug delivery technologies increasingly suggest that safer, more efficient treatment options are on the horizon. At the core of this potential are cannabinoids. Developments in this rapidly growing segment of the medical marijuana market are pioneered by a vast number of innovators, including Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) (LXRP Profile), GW Pharmaceuticals (NASDAQ: GWPH), Zynerba Pharmaceuticals (NASDAQ: ZYNE), Cara Therapeutics (NASDAQ: CARA) and Philip Morris (NYSE: PM), all of which are invested in the cannabis space.

Research findings in the cannabinoid field continue to astonish and elate. In August 2017, Lexaria Bioscience announced (http://nnw.fm/h7aG8) the world’s first clinical study on human volunteers of cannabidiol (CBD) within Lexaria’s high absorption TurboCBD™ product. The study will evaluate the effects of CBD on cardiovascular health and cognitive function. Lexaria’s TurboCBD, a brand of technologically enhanced, high absorption hemp oil capsules, came to market in March 2017. Its CBD content is fortified with high-quality American ginseng and ginkgo biloba for support of enhanced focus and memory, and reduced stress and fatigue.

TurboCBD capsules contain a combination of CBD and minute quantities of long chain fatty acids like sunflower oil, utilizing a proprietary technology to create an amalgam that increases the ability of the human gastrointestinal system to absorb CBD. In vitro and human focus study testing has shown increases in CBD absorption using Lexaria’s technology by as much as 5-10 times more than conventional preparations. Those studies also demonstrated rapid onset of action in as little as 15 minutes.

The TurboCBD study is designed to test a number of hypotheses expected to follow after its supplementation: (i) that circulating CBD and nitric oxide will increase in both young and old participants; (ii) that glucose and blood pressure will remain stable; and (iii) that vascular function, and cognitive and physical exercise performance will improve to a greater extent in older participants. The study will be conducted by researchers at the University of British Columbia, which has consistently been ranked as one of the top three universities in Canada. The institution is also considered one of the top research universities in the world and has conducted several earlier studies in the cannabis sector, available for review at http://nnw.fm/o8O9a.

Lexaria has also developed and commercialized a patented and cost-effective delivery technology, DehydraTECH™, which has been both laboratory and market proven to enhance the performance of beneficial compounds in ingestible products across four categories: taste, smell, speed of action, and bio-absorption and bio-availability.

At present, Lexaria is the only company in the world that has been awarded a patent for the improved (oral or ingestible, including pills) delivery of all non-psychoactive cannabinoids. Patents have been awarded in the U.S. and Australia and are pending in 40 more countries. This puts the company in the unusually advantageous position of owning proprietary technology that can deliver a vast range of non-psychoactive cannabinoid-based drugs.

Notably, because Lexaria’s technology is complimentary to all ingested forms of cannabinoids, the company is positioned to license its intellectual property to clinical-stage biotechnology companies, becoming an enabler – rather than a competitor – that works with other research and development pertaining to cannabinoids.

Collaboration with a company like GW Pharmaceuticals (GWPH), for example, would could yield considerable outcomes. The British company, best known for its multiple sclerosis (MS) cannabinoid product, Sativex, is working feverishly to bring another to market. Currently, its lead cannabinoid product candidate Epidiolex is in phase III clinical trials. This drug is a proprietary oral solution of pure plant-derived cannabidiol (CBD) for the treatment of severe, orphan, early-onset, treatment-resistant epilepsy syndromes including Dravet syndrome, Lennox-Gastaut syndrome (LGS), Tuberous Sclerosis Complex (TSC) and Infantile Spasms (IS).

Also developing treatments for epileptic conditions, with rather less encouraging outcomes than GW Pharmaceuticals, is Zynerba Pharmaceuticals (ZYNE). In August 2017, the company published disappointing results of phase II studies of its cannabidiol (CBD) product, ZYN002, aimed at treating adult epilepsy patients with focal seizures. Since CBD has shown some promise in reducing epileptic seizures, as in the GW Pharmaceutical studies, this raises the possibility that Zynerba’s setback may be due, not to the payload, but the delivery system. ZYN002 employs a transdermal gel that is applied topically on the surface of the skin. However, an oral delivery system, like the one developed by Lexaria, may prove more effective.

Cara Therapeutics (CARA) is another biotech now coming to terms with disappointing clinical trial results. Trials for an oral formulation of its drug candidate CR845, an opioid derivative, studied in osteoarthritis patients, did not turn out so well. However, the study tested patients on low dosages (1.0 mg and 2.5 mg) of CR845 taken orally. Higher oral dosages and CR845 taken intravenously have shown more promising outcomes. The company’s research into opioids has spilled over into cannabinoids. Current preclinical research involves CR701, a cannabinoid receptor agonist, designed to treat chronic pain. The incentive to develop cannabinoid products to treat chronic pain is driven, in part, by the opioid epidemic. While opioid overdose deaths are in the tens of thousands, there appears to be no clearly documented account of anyone dying from an overdose of marijuana.

Smoking marijuana is, of course, one method proven to deliver cannabinoids effectively. Alas, the now well-known deleterious effects on the respiratory system are spurring efforts to develop other delivery mechanisms, such as non-smoke cigarettes, which perhaps is why Philip Morris International (PM) invested $20 million in Israeli startup Syqe Medical. The company manufactures delivery devices for cannabis, like its inhaler. Syqe’s pocket-sized Inhaler delivers precision dosages of its payload: 100 micrograms, every time the device is activated. This overcomes a major barrier to adoption of medical cannabis by doctors: the lack of standardization in dosage regimens. Syqe has tested a similar device in hospitals in a clinical trial that demonstrated its dosing precision superiority to other modes of THC administration. With Philip Morris’ involvement, nicotine may just be next.

As the research into cannabinoids continues to unearth excitingly novel ways to treat a variety of medical conditions, delivery systems are proving to be just an important as payloads. As a result, companies with advanced delivery systems, like Lexaria, are likely to find cannabinoid biotechs beating that proverbial path to their door.

For more information on Lexaria Bioscience please visit: Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 613
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Previous

Return to QualityStocks Featured Companies

Who is online

Users browsing this forum: No registered users and 3 guests

cron